Liu Z, Le K, Zhou X, Alexander JL, et al. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a p Lancet Gastroenterol Hepatol 2022 Dec 5:S2468-1253(22)00389.
PMID: 36481043